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Evaluation of Pneumonia Virus of Mice as a Possible Human
Pathogen
Linda G. Brock,a Ruth A. Karron,b Christine D. Krempl,c Peter L. Collins,a and Ursula J. Buchholza
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USAa; Center for Immunization
Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USAb; and Institute of Virology and
Immunobiology, Julius-Maximilian University, Würzburg, Germanyc
Pneumonia virus of mice (PVM), a relative of human respiratory syncytial virus (RSV), causes respiratory disease in mice. There
is serologic evidence suggesting widespread exposure of humans to PVM. To investigate replication in primates, African green
monkeys (AGM) and rhesus macaques (n 4) were inoculated with PVM by the respiratory route. Virus was shed intermittently
at low levels by a subset of animals, suggesting poor permissiveness. PVM efficiently replicated in cultured human cells and in-
hibited the type I interferon (IFN) response in these cells. This suggests that poor replication in nonhuman primates was not due
to a general nonpermissiveness of primate cells or poor control of the IFN response. Seroprevalence in humans was examined by
screening sera from 30 adults and 17 young children for PVM-neutralizing activity. Sera from a single child (6%) and 40% of
adults had low neutralizing activity against PVM, which could be consistent with increasing incidence of exposure following
early childhood. There was no cross-reaction of human or AGM sera between RSV and PVM and no cross-protection in the
mouse model. In nativeWestern blots, human sera reacted with RSV but not PVM proteins under conditions in which AGM im-
mune sera reacted strongly. Serum reactivity was further evaluated by flow cytometry using unfixed Vero cells infected with
PVM or RSV expressing green fluorescent protein (GFP) as a measure of viral gene expression. The reactivity of human sera
against RSV-infected cells correlated with GFP expression, whereas reactivity against PVM-infected cells was low and uncorre-
lated with GFP expression. Thus, PVM specificity was not evident. Our results indicate that the PVM-neutralizing activity of hu-
man sera is not due to RSV- or PVM-specific antibodies but may be due to low-affinity, polyreactive natural antibodies of the IgG
subclass. The absence of PVM-specific antibodies and restriction in nonhuman primates makes PVM unlikely to be a human
pathogen.
Pneumonia virus of mice (PVM) is an enveloped nonseg-mented negative-strand RNA virus of the genus Pneumovirus,
family Paramyxoviridae (17, 23). PVM is a relative of human re-
spiratory syncytial virus (RSV). RSV is the leading viral cause of
severe respiratory infections in infants and also causes substantial
morbidity and mortality in the elderly and in profoundly immu-
nosuppressed individuals (17, 26, 59). Pneumoviruses have ge-
nomes of approximately 15 kb that contain 10 genes encoding 11
or 12 proteins. The gene order and constellation of proteins are
conserved within the genus, with the exception that the PVM P
gene encodes a second protein of unknown function (3, 41) that
does not have a counterpart in RSV. The degree of amino acid
sequence identity between PVMandRSV ranges from 10% (M2-2
protein) to 60% (nucleocapsid N protein) (41).
The host range and natural history of PVM are poorly under-
stood. PVM was first discovered in laboratory mice in 1938 in a
study to isolate human respiratory viruses from patients with re-
spiratory disease (33). In that study, human nasopharyngeal wash
specimens were serially passaged in mice. The inoculated animals
developed viral pneumonia; however, the same viral pneumonia
was also induced by serial passage of lung suspensions from noni-
noculated control mice. This observation led to the identification
of PVM as a causative agent of pneumonia in mice (32, 33). The
pathogenesis of PVM in inbred mice varies considerably between
strains (2); in the commonly used BALB/c strain, the virus is
highly pathogenic, with doses of 120 PFU and even lower being
lethal (19, 42). In the past, evidence of PVM infection of labora-
torymice was abundant (13, 37, 39, 40, 48, 70), and there has been
serologic evidence of infection of a number of other laboratory
animals, including other rodent species, rabbits, and nonhuman
primates (35). However, the virus has nowbeen largely eliminated
from laboratorymice by specific-pathogen-free breedingmethods
and infection control measures. For animals kept without these
measures, such as those in pet shops, evidence of PVM infection
has continued to be reported (20). While serologic evidence of
PVM infection in wild rodents also has been reported (38), most
surveys of wild rodents have failed to find such evidence (4, 22, 49,
52, 61). In addition, morbidity or mortality attributed to PVM
and isolation of the virus from wild rodents have not been docu-
mented. Thus, the natural host(s) and the natural history of PVM
remain unclear. More recently, PVMwas isolated from dogs with
respiratory tract disease, although whether PVM caused the ob-
served disease and is common in dogs is unclear (57).
The prevalence of PVM in captive animals has raised the sug-
gestion that it might arise from human contact. Indeed, two
groups have reported serological data suggesting that PVM, or an
antigenically related virus, causes widespread human infection
(31, 32, 34, 35, 56).However, these studies are difficult to interpret
for various reasons, including lack of a control for cross-reaction
between PVM and its highly prevalent RSV relative, the small
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number of screened sera, and the lack of experimental details suf-
ficient to allow for clear interpretation of the results. Attempts by
one group, reporting in the 1940s (31, 32, 34, 35), to detect PVM
in human specimens by the induction of antibodies in laboratory
animals was confounded by the likely presence of PVM in some of
those animals. A second group, reporting in 1986 (56), noted
moderate to high titers of PVM-neutralizing antibodies in more
than 75% of adult human sera, but reactivity with PVM proteins
was not confirmed, and well-defined negative and positive con-
trols were not used. A report of reciprocal cross-reactivity between
the N proteins of RSV and PVM highlighted the possibility of
cross-reaction in serologic studies (27, 44). To date, PVM has
never been reported to be isolated from humans. To investigate
the possibility of PVM or a PVM-like virus as a possible human
pathogen, we evaluated PVM replication in nonhuman primates,
evaluated cross-reactivity between PVM and RSV, and evaluated
in detail the reactivity of human sera with PVM.
MATERIALS AND METHODS
Viruses and cells. Recombinant PVM (rPVM) is based on a consensus
sequence for virulent strain 15 (42). rPVM, rPVM expressing green fluo-
rescent protein (rPVM-GFP) (42), and rPVM mutants lacking the genes
for nonstructural proteins NS1 and/or NS2 (rPVMNS1, rPVMNS2,
and rPVMNS12) (9)were propagated onBHK-21 cells (CCL-10; ATCC,
Manassas, VA) or on Vero cells (CCL-81; ATCC). Recombinant RSV
(rRSV) (18) or GFP-expressing RSV (RSV-GFP) (50) was propagated on
Vero cells. BHK-21 cells were maintained in Glasgow minimal essential
medium (Glasgow MEM; Life Technologies, Carlsbad, CA) supple-
mented with 4 mM L-glutamine, 2% MEM amino acids (Life Technolo-
gies), and 10% fetal bovine serum (FBS) (HyClone, Logan,UT). Vero cells
were maintained in Opti-Pro medium (Life Technologies) supplemented
with 4 mM L-glutamine. BSR T7/5 cells were maintained in Glasgow
MEM as described before (7). A549 cells (CCL-185; ATCC) were main-
tained in F-12 medium (Life Technologies) supplemented with 5% FBS
and 4 mM L-glutamine.
RSV or PVM titers were determined by plaque assay on Vero cells
under a 0.8% methylcellulose overlay. Plaques were visualized by immu-
nostaining with rabbit G-specific polyclonal antibody (PAb) raised
against recombinantmodified vaccinia virus Ankara (MVA)-PVMG (42)
or using a mixture of monoclonal antibodies (MAbs) 1129, 1269, and
1243 against the RSV F protein (5), followed by a horseradish peroxidase-
labeled goat anti-rabbit or anti-mouse IgG secondary antibody (KPL,
Gaithersburg,MD). Bound antibodies were detected by incubationwith a
peroxidase substrate (KPL).
To prepare sucrose gradient-purified virus, clarified medium super-
natants from virus-infected Vero cells were subjected to centrifugation on
discontinuous sucrose gradients (30 to 60% wt/vol) at 26,700 g for 2 h.
The virus band between the 30 and 60% interface was collected, diluted
with Opti-MEM (Life Technologies), and pelleted by centrifugation at
8,000 g for 2 h at 4°C. Pellets were resuspended in Opti-MEM for use in
infectivity assays or in TEN buffer (10 mM Tris [pH 7.4], 1 mM EDTA,
and 100 mM NaCl) for Western blot analysis. Virus samples were flash
frozen on dry ice. UV inactivated rPVMNS2was prepared by irradiation
with 240 kJ using a UV Stratalinker 1800 (Stratagene, La Jolla, CA). The
absence of infectious virus was confirmed by plaque titration.
Nonhuman primate studies. Four young adult African green mon-
keys (AGM; Chlorocebus aethiops) and four rhesus macaques (RM;
Macaca mulatta) were confirmed to be seronegative for PVM and RSV by
plaque reduction assays, which sensitively detect even low levels of activ-
ity. The animals were inoculated simultaneously intranasally and intra-
tracheally with 1ml of inoculumper site containing 106.8 PFU of rPVM in
L15 medium (Life Technologies). Clinical observations were made on
days 0 to 12 postinoculation. Following inoculation, nasopharyngeal
(NP) swabs were collected daily for 10 days and on day 12. Tracheal lavage
(TL) samples were collected on days 2, 4, 6, 8, 10, and 12 postinfection.
The amount of virus present in NP and TL samples was quantified by
plaque titration on Vero cells. All animal experiments were approved by
the Animal Care and Use Committee of the National Institute of Allergy
and Infectious Diseases. The studies were performed in accordance with
the recommendations in the Guide for the Care and Use of Laboratory
Animals (50a).
Virus-specific control antibodies.Control antibodies specific to RSV
included the F-specific mouse MAb 1129 (5), rabbit antiserum raised
against sucrose gradient-purified RSV (RSV-specific PAb), and AGM sera
collected 35 days following experimental infection with RSV. Control
antibodies specific to PVM included rabbit antiserum raised againstMVA
expressing the PVM F or G protein (PVM F-specific PAb and PVM G-
specific PAb, respectively) (42), rabbit antiserum raised against sucrose-
gradient-purified PVM (PVM-specific PAb), and post-PVM-infection
AGM sera from the experiment whose results are shown in the tables.
Virus neutralization assays.Human sera were obtained from healthy
adult donors at the Department of Transfusion Medicine of the National
Institutes of Health (NIH, Bethesda, MD) under a protocol approved by
the institutional review board of the Clinical Center at the NIH. Written
informed consent was obtained from all donors. Sera fromhealthy infants
and children ages 6 to 18months were provided by Ruth Karron from the
Center for Immunization Research (CIR), Johns Hopkins University
School of Public Health (Baltimore, MD), under a protocol approved by
the JohnsHopkins Institutional Review Board.Written informed consent
was obtained from a parent before each child’s enrollment. All human
sera were provided without patient identifiers. The 60% plaque reduction
neutralizing-antibody titers (PRNT60) were determined in a plaque re-
duction neutralization assay on Vero cells (16) using GFP-expressing
rRSV and rPVM. Prior to use, serum sampleswere incubated for 30min at
56°C to inactivate complement. In the case of RSV-GFP, 10% of the final
volume was guinea pig complement (Lonza, Walkersville, MD), as is typ-
ical for RSV neutralization assays (69). Complement was not used with
PVM because it inactivates the virus. Plaques were visualized by GFP
expression using a Typhoon imager (GE Healthcare, Piscataway, NJ).
qRT-PCR and ELISA. Total RNA was isolated from infected cells us-
ing an RNeasy total RNA isolation kit (Qiagen, Valencia, CA) and treated
withDNase to remove residual genomicDNA.Onemicrogramof isolated
RNAwas reverse transcribed using SuperScript II (Life Technologies) and
random primers. Two microliters of the cDNA mix was used for duplex
quantitative reverse-transcription PCRs (qRT-PCRs) using a Brilliant
QRT-PCR Plus core kit (Life Technologies) for human alpha and beta
interferons (IFN- and -) (6-carboxy-2=,4,4=,5=,7,7=-hexachlorofluores-
cein [HEX]-labeled probe) with -actin as the housekeeping gene (6-
carboxyfluorescein [FAM]-labeled probe) (62). CXCL10 primers (5=-TG
GCATTCAAGGAGTACCTCTC-3= and 5=-CAAAATTGGCTTGCAGG
AAT-3=) and a HEX-labeled probe (5=-CCGTACGCTGTACCTGCATC
AGCA-3=) were designed by using the website Primer 3 (http://frodo.wi
.mit.edu/primer3/). PVM primers and probes were described previously
(9). IRF7, ISG56 (IFIT1), and 18S RNA were quantified using TaqMan
primer-probe sets and Universal PCR master mix (Life Technologies).
Results were analyzed using the comparative threshold cycle (CT)
method, normalized to either-actin (IFN-a and - andCXCL10) or 18 S
RNA (ISG56 and IRF7), and expressed as fold change over the values for
UV-rPVMNS2 controls 24 h postinfection. Commercial enzyme-linked
immunosorbent assay (ELISA) kits were used to determine the concen-
trations of IFN- and - (Life Technologies) and of IP-10 and CXCL10
(R&D Systems, Minneapolis, MN) in cell culture supernatants.
Western blots. Sucrose-gradient-purified RSV and PVM were resus-
pended in TEN buffer (10mMTris [pH 7.4, 1 mMEDTA, and 100mM
NaCl). For electrophoresis, viral particles were prepared in 1 NuPAGE
lithium dodecyl sulfate (LDS) sample buffer (Life Technologies), and the
highest exposure temperature was 32°C. PVM N and P proteins were
identified in cell lysates of BSR T7/5 cells transfected with protein expres-
sion plasmids (42) previously prepared for PVMN and P. Cell lysis buffer
Brock et al.
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containing 1 protease inhibitor (Roche, Indianapolis, IN) and 1 Nu-
PAGE LDS sample buffer was applied to BSR T7/5monolayers. Cells were
scraped and homogenized using a QIAshredder (Qiagen, Valencia, CA).
For electrophoresis, cell lysates were diluted in 1 NuPAGE reducing
buffer (Life Technologies) and 1 LDS sample buffer and heat denatured
at 95°C for 5 min.
One microgram of cell lysates and viral particles was separated on
NuPAGE 4-to-12% bis-Tris sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) gels withMOPS (morpholinepropanesulfo-
nic acid) electrophoresis buffer (Life Technologies) in parallel with an
Odyssey two-color protein molecular weight marker (Li-Cor, Lincoln,
Nebraska). Proteins were transferred to polyvinylidene difluoride
(PVDF) F membranes (Millipore, Billerica, MA) in 1 NuPAGE buffer.
Themembranes were blocked with Odyssey blocking buffer (Li-Cor) and
incubated with primary antibody in the presence of 0.1% Tween 20. The
primary antibodies and the dilutions used were as follows: RSV F-specific
mouse MAb 1129, 1:10,000 (5); rabbit RSV-specific PAb, 1:15,000; RSV-
specific AGM antiserum, 1:100; rabbit PVM-specific PAb, 1:5,000; PVM
F-specific PAb, 1:1,000; and PVM-specific AGMantiserum from the pres-
ent study, animalW879, 1:300,000. Human sera fromdonors with known
PVM-neutralizing titers were used at a dilution of 1:100. The secondary
antibodies (used at a 1:10,000 dilution) were as follows: goat anti-monkey
IgG (KPL, Gaithersburg, MD), donkey anti-human IgG IRDye 700DX
(Rockland Immunochemicals, Gilbertsville, PA), goat anti-rabbit IgG
IRDye 800 (Li-Cor), and goat anti-mouse IgG IRDye 800 (Li-Cor). The
goat anti-monkey IgG antibody was conjugated to IRDye 800CW using
the IRDye 800CW Microscale protein-labeling kit (Li-Cor). Membrane
strips were scanned on an Odyssey infrared imaging system, and back-
ground was corrected using Odyssey software, version 3.0 (Li-Cor).
Flow cytometry. Vero cells were infected with rRSV-GFP or rPVM-
GFP at a multiplicity of infection (MOI) of 1. Twenty-four hours postin-
fection, cells were detached using 1 mM EDTA in phosphate-buffered
saline (PBS) supplemented with 3% FBS. Three washes were performed
after incubation with primary and secondary antibodies. The cells were
blocked by incubation in 3% bovine serum albumin (BSA) in PBS sup-
plemented with 0.5 mM EDTA for 20 min on ice. Human and AGM sera
with known RSV and PVM PRNT60 were used at dilutions of 1:100,
1:1,000, and 1:5,000. Prior to use, the serum samples were incubated for
30min at 56°C to inactivate complement. RSVFmouseMAb1129 (5) and
rabbit G-specific PAb were included as positive controls (1:1,000). The
secondary antibodies used in these experiments included goat anti-mon-
key IgG (KPL), goat anti-monkey IgM (KPL), donkey anti-human IgG
Alexa 647 (Life Technologies), donkey anti-human IgM Alexa 647 (Life
Technologies), goat anti-rabbit IgG (KPL), and goat anti-mouse IgG
(KPL). The goat anti-monkey antibodies, goat anti-rabbit IgG, and goat
anti-mouse IgGwere conjugated to Alexa 647 by the NIHNIAIDCustom
Antibody Conjugation Facility (Rockville, MD). After incubation with
secondary antibody, the samples were treated with blue Live/Dead stain
(Life Technologies) to monitor cell viability. The samples were then fixed
with BD Cytofix (BD Biosciences, San Jose, CA). Flow cytometry analysis
was performed on an LSR II flow cytometer (BD Biosciences). Data com-
pensation was performed using mouse CompBeads (BD Biosciences), an
ArC amine-reactive compensation kit (Life Technologies), and rRSV-
GFP- or rPVM-GFP-infected cells. The data acquired from compensation
controls were automatically calculated using BD FACSDiva, version 6.1.3
(BD Biosciences). The data were analyzed using FlowJo software, version
7.6.3 (Tree Star, Ashland, OR). The compensated data were gated using
the following pathway: first, a uniform cellular population was identified
by using side scatter versus forward scatter; second, the uniform popula-
tion was gated on forward scatter height versus forward scatter area to
eliminate cell clusters and identify single cells; and third, the single cell
population was gated on forward scatter versus Live/Dead to eliminate
dead cells and identify live cells at the time of staining.
IgGdepletion. Serum samples were passed over a proteinG Sepharose
column (GE Healthcare). To confirm that IgG had been successfully de-
pleted, serum samples were electrophoresed on a 4-to-12% SDS-PAGE
gel with MOPS electrophoresis buffer (Life Technologies) under nonre-
ducing and nondenaturing conditions. Gels were stained with Coomassie
blue (Life Technologies) to visualize IgG protein bands; human IgG was
used as a positive control (Pierce Biotechnology, Rockford, IL). Band
intensities were quantified using ImageJ software (NIH, Bethesda,
MD). Statistical analysis to compare pre- and post-IgG-depletion neu-
tralization titers was done using GraphPad Prism 5 (GraphPad Soft-
ware, La Jolla, CA).
RESULTS
PVM replication is highly restricted in nonhuman primates.
Sera from 39 AGM and 20 RMwere screened for PVM-neutraliz-
ing activity by a plaque reduction neutralization assay (data not
shown). PVM-neutralizing activity (which is defined in this study
by a cutoff of 5.3 reciprocal log2 [1:40]) was not detected in
any animal, indicating that the 59 animals, which were obtained
from breeding colonies at Morgan Island, SC, and St. Kitts in the
Caribbean, lacked pre-existing immunity to PVM. Four each of
these PVM-seronegative AGM and RM were inoculated intrana-
sally and intratracheally with the high dose of 6.8 log10 PFU of
PVM per site (total dose, 7.1 log10 PFU per animal) using low-
passage, cDNA-derived PVM (rPVM) that had previously been
shown to be highly virulent in mice (9). Nasopharyngeal swabs
and tracheal lavage samples were collected over a period of 12 days
and analyzed by plaque titration to monitor virus shedding in the
upper and lower respiratory tracts, respectively (Tables 1 and 2).
From the upper respiratory tract, virus shedding was not detected
in any AGM, and very low levels of shedding were detected in 2 of
the 4 RM (Table 1). From the lower respiratory tract, low levels of
shedding were detected in 3 of the 4 AGM and in 1 of the 4 RM
(Table 2). No virus was recovered from either site in 3 animals
(AGM W994, RHDA4G, and RHDA43). No clinical symptoms
were observed in any animal.
Analysis of sera collected on day 28 postinfection showed that
all of theAGMandRMdeveloped remarkably high levels of PVM-
neutralizing serum antibodies (Table 3) (mean PRNT60 of 24.2
log2 [1:19,272,000] for AGM and 13.9 log2 [1:15,290] for RM),
even the animals in which replication had not been detected. This
suggested that all of the monkeys had been infected with rPVM,
even in the absence of detectable shedding. Thus, PVM replicated
in the upper and lower respiratory tracts of two species of nonhu-
man primates, but replication was highly restricted, and shedding
was observed in only a subset of animals.
PVMIFNantagonist proteins control type I IFN induction in
human cells. As a preliminary investigation of the host range re-
striction of PVM in primates, we evaluated (i) the ability of PVM
to replicate in primate cells, specifically in the human lung epithe-
lial cell line A549, and (ii) the ability of PVM to control the type I
interferon (IFN) response in these cells, since controlling the host
IFN response is an important factor in the ability of viruses in
general to replicate. A549 cells were chosen for this experiment
because of their human respiratory epithelial origin and because
they are widely used to study IFN responses. PVM had previously
been reported to replicate in the primate BSC-1 cell line, but that
particular PVM strain had previously been passaged extensively in
cell culture, had lost virulence inmice, and had exhibited evidence
of widespread mutations (64). In addition to wild-type rPVM, we
also evaluated rPVMmutants lacking theNS1 gene (rPVMNS1),
the NS2 gene (rPVMNS2), or both the NS1 and NS2 genes
(rPVMNS12) (9). The PVMNS2 protein was previously identi-
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fied as an inhibitor of murine type I IFN induction, with a minor
contribution from NS1 (9, 28).
Monolayer cultures of A549 cells were infectedwith the various
viruses at an MOI of 0.1 PFU/cell in order to evaluate multicycle
replication (Fig. 1). rPVM reached a peak titer of approximately
4.2 log10 PFU perml on day 10 (Fig. 1). This titer is comparable to
what we routinely obtain with RSV in A549 cells (62), showing
that these human cells are similarly permissive for PVM and RSV.
Peak titers of rPVMNS1 (4.7 log10 PFU per ml on day 10) were a
little higher than those of wild-type rPVM, possibly reflecting a
slight replication advantage due to a shorter genome resulting
from the gene deletion. Peak titers for rPVM lacking NS2 (3.5
log10 PFU per ml), or both NS1 and NS2 (3.0 log10 PFU per ml),
occurred earlier (day 4) and at lower levels than those for rPVM
and rPVMNS1 and subsequently declined. Thus, viruses lacking
the NS2 gene (rPVMNS2 and rPVMNS12) were substantially
restricted for replication in A549 cells, whereas deletion of NS1
alone had little effect on the replication of rPVM. These results are
similar to those previously observed in mouse embryo fibroblasts
(9, 28).
Next, we analyzed the type I IFN response inA549 cells infected
with the wild-type and NS deletion rPVM strains using prepara-
tions that had been purified on sucrose gradients in order to re-
duce contamination from small molecules, including cytokines.
Replicate cultures of A549 cells were inoculated with each virus at
an MOI of 3 PFU/cell or with UV-inactivated rPVMNS2 as a
control, and the cultures were incubated and harvested at 24, 44,
and 64 h postinfection. Plaque titration of clarified medium su-
pernatants from the 64-h time point showed that the titers of the
various viruses were similar (Fig. 2A). Cell-associated viral RNA
was quantified by qRT-PCR using primers specific to the PVM N
and F genes (Fig. 2B). This showed that, at the earlier time points
(24 and 44 h), there was somewhat more N and F RNA in cells
infected with rPVM lacking NS2 (rPVMNS2 and rPVMNS12)
than in those infected with wild-type rPVM and rPVMNS1.
However, by 64 h the levels of RNA were similar for all viruses.
From this same experiment, we evaluated the expression of
IFN- and - by qRT-PCR of cell-associated RNA and by ELISA
of clarified medium supernatants (Fig. 2C). Consistent with our
previous observations with mouse embryo fibroblasts (9, 28),
rPVMand rPVMNS1 induced little or no IFN- or - detectable
by qRT-PCR or ELISA at any time point, whereas strong IFN-
and - responses detected by both methods were induced by
rPVM lackingNS2 or lacking bothNS1 andNS2. This showed that
TABLE 1 Viral titers of NP swabs from AGM and RM inoculated with rPVMa
Group ID
Virus titer (log10 PFU/ml) on day: Peak titer
(log
10
PFU/ml)
Days of
sheddingb1 2 3 4 5 6 7 8 9 10 12
AGM W879 — — — — — — — — — — —  0.7 0
W877 — — — — — — — — — — —  0.7 0
W872 — — — — — — — — — — —  0.7 0
W994 — — — — — — — — — — —  0.7 0
Mean — —
RM RHCL7C — — — 1.7 0.7 — 2.2 1.7 — — — 2.2 5
RHCL7E — — — 1.7 1.4 — — 1.7 1.0 — — 1.7 6
RHDAG — — — — — — — — — — —  0.7 0
RHDA43 — — — — — — — — — — —  0.7 0
Mean 1.3 0.4 2.8 1.6
a Monkeys were inoculated intranasally and intratracheally with 6.8 log10 PFU of PVM per site (total dose, 7.1 log10 PFU per animal). NP swabs were collected on the indicated
days. Virus titrations were performed on Vero cells at 37°C. The lower limit of detection was 0.7 log PFU/ml. —, no detectable virus. The calculation of means used a value of 0.7
for samples with undetectable virus.
b Number of days from the day of the first recorded titer to the day of the last recorded titer.
TABLE 2 Viral titers of TL samples from AGM and RM inoculated with rPVMa
Group ID
Virus titer (log10 PFU/ml) on day:
Peak titer
Days of
sheddingb2 4 6 8 10 12
AGM W879 — 2.9 1.5 — — — 2.9 5
W877 0.7 — 1.3 — — — 1.3 7
W872 — — 1.3 — — — 1.3 3
W994 — — — — — — 0.7 0
Mean 1.5 0.5 3.8 1.5
RM RHCL7C — — — — — — 0.7 0
RHCL7E — — 1.0 1.9 — 0.7 1.9 9
RHDA4G — — — — — — 0.7 0
RHDA43 — — — — — — 0.7 0
Mean 1.0 0.3 2.3 2.3
a In the experiment whose results are shown in Table 1, TLs were performed on the indicated days. Virus titers were determined by plaque assay as described for Table 1. —, no
detectable virus. The calculation for means used a value of 0.7 for samples with undetectable virus.
b Number of consecutive days starting 1 day before the first recorded titer and ending 1 day after last recorded titer.
Brock et al.
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NS2 is functional as an efficient inhibitor of type I IFN induction
in human cells, just as in mouse cells. IFN- and - gene expres-
sionwas detected starting at 24 h postinfection, wasmaximal at 44 h,
and decreased at 64 h. IFN protein expression lagged behind: it was
not detectable at 24 h but reached high levels at 44 h and 64 h.
We also evaluated induction of IFN-stimulated genes by qRT-
PCR (ISG56, IRF7, and CXCL10) and by ELISA (CXCL10) (12,
29, 30, 36, 55) (Fig. 2D).We detected strong induction of all three
genes in cells infected with rPVMNS2 or NS1/2, whereas little
or no induction was detected in response to wild-type rPVM or
rPVMNS1. Peak expression of all three genes was somewhat
higher with virus lacking both NS1 and NS2 than with virus lack-
ing only NS2, suggesting the possibility that NS1may inhibit IFN-
inducible genes in human cells to some extent. This will be exam-
ined in future studies.
PVM-neutralizing activity in infant and adult sera. As the
next step in evaluating PVM as a possible human pathogen, we
analyzed sera from 30 adult donors and from 17 infants and chil-
dren, 6 to 18 months of age, for the presence of PVM- and RSV-
neutralizing antibodies using plaque reduction neutralization as-
says (Fig. 3). Serum from each adult human donor had a high titer
of RSV-neutralizing antibody, as would be expected for this ubiq-
uitous pathogen, with an average PRNT60 of 9.1 log2 (1:549). In
addition, 12 (40%) of the adult donor sera also had PVM-neutral-
izing activity, although these titers were relatively low, with an
average PRNT60 of 6.7 log2 (1:104) (Fig. 3). There was no evident
concordance between high RSV titers and the presence of PVM-
neutralizing activity. For example, the four donors with the high-
est RSV-neutralizing activities (Fig. 3, dots 1 to 4) had no or low
PVM-neutralizing activities. This was investigated further for all
of the samples using the Wilcoxon signed-rank test, which con-
firmed a lack of correlation (P  0.001). This suggested that the
observed PVM-neutralizing activity is unlikely to be due to cross-
reaction by RSV-specific antibodies.
Seven of 17 (41%) of the sera from infants and young children
were seropositive for RSV, and in most cases the titers of RSV-
neutralizing antibodies were lower than those in adults (average
PRNT60 of 7.2 log2; 1:142). Only one of the pediatric sera had
detectable, but low, PVM-neutralizing activity (6.2 log2; 1:72),
and this particular specimen was RSV seronegative (Fig. 3, dot 5).
The apparent increase in PVM seroprevalence from early child-
hood into adulthood could be consistent with increasing exposure
during life to PVM or a PVM-like virus.
Lack of cross-neutralization between RSV and PVM. As
noted above, the lack of concordance between the titers of RSV- and
PVM-neutralizing antibodies suggested that the PVM-neutralizing
activity was not due to cross-neutralization by RSV-specific anti-
bodies. To further investigate the possibility of cross-neutraliza-
tion, we performed neutralization assays with AGM sera collected
28 days following infection with rPVM (from the experiment de-
scribed above) or with AGM sera collected 35 days following in-
fection with recombinant wild-type RSV, strain A2 (rRSV; P. L.
Collins andU. J. Buchholz, unpublished data), thus providing sera
specific to either virus without the confounding presence of anti-
bodies to the other virus. The mean PRNT60 of the RSV-specific
and PVM-specific AGM control sera were 8.0 log2 (1:256) and
24.2 log2 (1:19,272,000), respectively; it was interesting that much
higher titers were induced by PVM even though RSV replicates to
higher titers in AGM. When tested individually (Fig. 3), none of
the RSV-specific AGM sera had cross-neutralizing activity with
rPVM, nor did any of the strongly neutralizing PVM-specific sera
have cross-neutralizing activity with RSV. Thus, monospecific
AGM sera induced by infection with either rRSV or rPVM do not
have detectable neutralizing activity against the heterologous
virus.
Lack of cross-protection between RSV and PVM in the
mouse model. We further evaluated cross-protection between
RSV and PVM in the mouse model. Groups of 15 mice each were
infected intranasally with PVM and RSV or mock infected. Since
wild-type PVM is lethal for mice even at relatively low doses, we
used two attenuated PVM derivatives: (i) rPVM-GFP, which is
slightly attenuated due to the presence of the GFP insert (42), was
administered at the very low dose of 10 PFU/mouse, and (ii)
rPVMNS2, which is highly attenuated and apathogenic (9), was
administered at a dose of 2,000 PFU per mouse. RSV was admin-
istered at 5.7 log10 PFU, which is a typical dose and well tolerated
FIG 1 Multistep growth kinetics of rPVM, rPVMNS1, rPVMNS2, and
rPVMNS12 in A549 cells. Duplicate monolayer cultures of human A549
airway epithelial cells were infected at an MOI of 0.1 PFU/cell with the indi-
cated virus. Supernatant aliquots were taken at 24-h intervals postinfection
and replaced with an equivalent volume of fresh medium. Viral titers were
determined by plaque assay in duplicate for each time point. Data are means
with standard errors, although inmany cases the error bars are obscured by the
symbols because the errors were very small. The limit of detection is 0.7 log10
PFU per ml (dashed line). Data are representative of two independent exper-
iments.
TABLE 3 PRNT60 in serum samples from AGM and RM inoculated
with rPVMa
Group ID
PVM PRNT60 (reciprocal log2)
b
Day 0 Day 28
AGM W879 3.7 36.6
W877 3.5 20.5
W872 4.8 27.1
W994 4.1 12.7
Mean: 4.0 0.6 24.2 10.1
RM RHCL7C 3.5 12.2
RHCL7E 3.5 12.0
RHDA4G 3.8 16.1
RHDA43 3.9 15.3
Mean: 3.7 0.2 13.9 2.1
a From the experiment described in Table 1, sera were collected 28 days postinfection.
PVM-neutralizing activity was measured by determining the 60% plaque reduction
neutralizing-antibody titer (PRNT60).
b The lower limit of detection of the PRNT60 assay was 2.5 (reciprocal log2). A serum
sample was considered positive with a PRNT60 value of5.3.
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FIG 2 Analysis of the type I IFN response in A549 cells infected with rPVM, rPVMNS1, rPVMNS2, or rPVMNS12 by qRT-PCR and ELISA. Triplicate
cultures of A549 cells weremock infected, infected with sucrose gradient-purified rPVM, rPVMNS1, rPVMNS2, or rPVMNS12 at anMOI of 3 PFU/cell, or
infected with sucrose gradient-purified UV-inactivated rPVMNS2. Cell cultures were harvested at the indicated time points, the medium supernatants were
clarified and used for quantification of viral titers and secreted cytokines, and the cell pellets were processed to purify total cell-associated RNA. (A) PVM titers
(log10 PFU per ml) at 64 h postinfection measured by plaque assay of medium supernatants (9). (B) Levels of cell-associated PVM F and N RNA measured by
qRT-PCR. (C) Levels of cell-associated IFN- and IFN- RNA measured by qRT-PCR (top) and levels of IFN- and IFN- protein in medium supernatants
measured by ELISA (bottom). (D) Levels of cell-associated ISG56, IRF7, andCXCL10RNAmeasured by qRT-PCR (top) and level of CXCL10 protein inmedium
supernatants measured by ELISA (bottom). All qRT-PCR results are expressed as difference (fold) relative to values in cells 24 h after inoculation with
UV-inactivated rPVMNS2.
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in mice. Five mice of each inoculated group were sacrificed to
evaluate virus replication: sacrifice was at day 4 for the RSV and
rPVMNS2 groups, which has been shown to be the time ofmax-
imum viral replication, and sacrifice was at day 11 for the rPVM-
GFP group in order to confirm that the PVM infectionwas cleared
(Fig. 4). We detected moderate levels of replication of RSV and
rPVMNS2, as expected, and confirmed that rPVM-GFP had
been cleared from the animals.
Four weeks after immunization, 5 mice of each group were
challenged intranasally with 2,000 PFU of rPVM (Fig. 4), a dose
that would be highly lethal for nonimmunemice, and 5 animals in
each group were challenged with 5.7 log10 PFU of RSV (Fig. 4). All
of the mice that had been immunized with rPVM-GFP or
rPVMNS2 were completely protected against PVM challenge,
whereas the level of replication of PVM in mice that had been
immunized with RSV was indistinguishable from that of the
mock-infected group (Fig. 4). Thus, immunizationwith RSV pro-
vided no detectable restriction of PVM replication. Conversely,
mice that had been immunized with RSV were completely pro-
tected against RSV challenge, whereas the replication of challenge
PVM was not reduced (Fig. 4). Thus, cross-protection did not
occur between PVM and RSV in a mouse immunization and
cross-challenge study.
Human sera with PVM-neutralizing activity did not react
with PVM proteins in Western blots. Since the PVM-neutraliz-
ing activity in the human sera did not appear to be due to cross-
reaction with RSV-specific antibodies, we investigated reactivity
of the sera with RSV (Fig. 5A) and PVM (Fig. 5B) proteins by
Western blot analysis, using nondenaturing and nonreducing
conditions. Control protein preparations and sera were used to
identify major RSV and PVM proteins (Fig. 5). The RSV F and N
proteins were identified in blots of sucrose gradient-purified rRSV
FIG 3 RSV- and PVM-neutralizing antibodies in human serum samples from
30 adults and 17 infants and young children. PRNT60weremeasured by plaque
reduction neutralization assays against PVM and RSV. Sera from RSV- and
PVM-infected AGM served as monospecific controls and also provided eval-
uation of possible cross-neutralization. Sera with a PRNT60 of5.3 log2 (1:
40) were considered seropositive (dashed line). Data points for PVM-seropos-
itive adult donors are circled. Some donors are identified by numbered dots to
allow comparison of titers of RSV- and PVM-neutralizing antibodies. Associ-
ation between titers of RSV- and PVM-neutralizing antibodies in human sera
among adults was calculated using a Wilcoxon signed rank test (***, P 
0.001). Data are representative of two (human sera) and three (AGM sera)
independent experiments.
FIG 4 Evaluation of cross-protection between RSV and PVM in the mouse
model. Six-week-old BALB/c mice in groups of 15 were immunized by intra-
nasal inoculation (80-l volume) under light methoxyflurane (Metofane) an-
esthesia on day 0with L15medium (as themock-infected control) orwithRSV
(500,000 PFU), rPVM NS2 (2,000 PFU), or rPVM-GFP (10 PFU). On day 4
(RSV and rPVMNS2 groups) or day 11 (rPVM-GFP group), 5 mice from
each group were euthanized, and virus titers in lung homogenates (log10 PFU
per g of lung) were determined by plaque assay (top). On day 28, 5 animals
from each group were challenged by intranasal administration of PVM (2,000
PFU) (middle), and the remaining 5 animals in each group were challenged by
intranasal administration of RSV (500,000 PFU) (bottom). Lungs were har-
vested 4 days postchallenge, and virus titers were determined by plaque titra-
tion. Group means are indicated by solid lines. The limit of detection was 1.7
log10 PFU per g of tissue (dashed line).
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FIG5 Western blot analysis of the 12 adult human serawith PVM-neutralizing activity. The presence of RSV- and PVM-specific antibodies in the 12 adult serum
samples with significant PVM-neutralizing activity was investigated by Western blot analysis against sucrose-gradient-purified rRSV or rPVM. Other lanes
contain control protein preparations and control antibodies to identify viral proteins. Protein samples were subjected to 4-to-12%SDS-PAGE gel electrophoresis
under nonreducing and nondenaturing conditions and then transferred to a PVDFmembrane. In the case of human test sera and AGM control sera, the serum
dilutions used and the RSV or PVM log2 PRNT60 of the undiluted sera are indicated above eachmembrane strip. Note that the RSV- and PVM-seropositive AGM
control sera were used at dilutions designed to have PRNT60 similar to that of the human test sera. Data are from one of three independent experiments with
similar results. (A) Reactivity with RSV proteins. The left and center panels (lanes a to g) show controls to identify viral protein species. Lanes a to c, rabbit
polyclonal antibody raised against gradient-purifiedRSV (RSV-specific PAb) reactedwithmock-infected cell lysate (a) and gradient-purified rRSV (b) and rPVM
(c). Lane d, RSV F MAb 1129 (5) reacted with gradient-purified rRSV. Lanes e to g, RSV-specific AGM serum reacted with mock-infected cell lysate (e) and
gradient-purified rPVM (f) and rRSV (g). The right panel shows results for the 12 human test sera reacted with blots prepared from gradient-purified rRSV. (B)
Reactivitywith PVMproteins. The left and center panels (lanes a to i) show controls to identify viral protein species. Lanes a to c, rabbit polyclonal antibody raised
gradient purified PVM (PVM-specific PAb) reacted with lysates of cells that had been mock-transfected (a) or transfected with plasmid expressing the PVM N
(b) or P protein (c). Lanes d and e, same PVM-specific PAb reacted with gradient-purified rRSV (d) or rPVM (e). Lane f, rabbit polyclonal antiserum raised
against a recombinant vaccinia virus expressing the PVMF protein (PVMF-specific PAb) reacted with gradient-purified rPVM. Lanes g to i, PVM-specific AGM
serum reacted with mock-infected cell lysate (g) and gradient-purified rPVM (h) and rRSV (i). The right panel shows results for the 12 human test sera reacted
with gradient-purified rPVM.
Brock et al.
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preparations using polyclonal rabbit serum raised against gradi-
ent-purified RSV (RSV-specific PAb) (Fig. 5A, lane b) and the
RSVF-specificmousemonoclonal antibody (MAb) 1129 (5) (lane
d). This showed that the RSV F protein migrated as an apparent
trimer, consistent with a nondenatured, nonreduced state. A
largely native conformation for F also is supported by its reactivity
with the F-specific MAb, which does not bind efficiently to dena-
tured protein. The rabbit RSV-specific PAb also showed slight
cross-reactivity with the PVM N protein in blots of gradient-pu-
rified rPVM (Fig. 5A, lane c). This is consistent with the previous
reports of reciprocal cross-reactivity between the N proteins of
RSV and PVM (27, 44).
In the case of PVM,we used a rabbit antiserum against purified
PVM (PVM-specific PAb) to identify the PVM N (43 kDa) and P
(39 kDa) proteins in blots of lysates of cells transfected with plas-
mids expressing the PVMNorPprotein (Fig. 5B, lanes b and c). In
addition, analysis of blots of gradient-purified PVM using the
same antiserum detected the PVM N and P proteins as well as a
diffuse band of 55 to 75 kDa corresponding to the G protein
(Fig. 5, lane e). There was a slight cross-reactivity of this serum
with the RSV N protein in purified rRSV (Fig. 5B, lane d). In
addition, the PVM F protein was identified in a blot of gradient-
purified PVMusing a rabbit serum (PVMF-specific PAb) that had
been made using anMVA expressing the PVM F protein (Fig. 5B,
lane f). This showed that the PVM F protein migrated entirely as
an apparent trimer under these nonreducing, nondenaturing con-
ditions.
As additional controls, we tested the reactivity of RSV- and
PVM-seropositive control AGM sera (Fig. 5A, lanes e to g, and B,
lanes g to i). Prior to use, these sera were diluted to levels of virus-
neutralizing activity comparable to those of the human test sera
(the RSV-specific serum was diluted 100-fold to an RSV PRNT60
of 9.4 log2, and the PVM-specific serum was diluted 300,000-fold
to a PVM PRNT60 of 6.6 log2). Under these conditions, the RSV-
seropositive AGM serum reacted strongly with RSV F in blots of
gradient-purified rRSV (Fig. 5A, lane g) and not with any proteins
fromgradient-purified rPVM(Fig. 5A, lane f). The PVM-seropos-
itiveAGMserum reacted stronglywith the PVMGprotein in blots
of gradient-purified rPVM (Fig. 6B, lane h) and not with blots of
gradient-purified rRSV (lane i). Sera from the seven other PVM-
infected AGM and RM for which data are presented in Tables 1 to
3 also reacted predominantly with the PVM G protein (data not
shown). It is interesting that the RSV-seropositive sera reacted
mainly with the RSV F protein, while the PVM positive sera re-
acted with G.
We then used thisWestern blot assay to investigatewhether the
12 adult human sera with PVM-neutralizing activity (Fig. 3) re-
acted with RSV and PVM proteins. Each of these sera reacted
strongly with the RSV F protein (Fig. 5A), which was expected
since all had strong RSV-neutralizing activity (Fig. 3). To various
degrees, 11 of 12 donors also reacted with the RSVN protein (Fig.
5A). However, none of the 12 sera detected any PVM protein,
under conditions in which PVM-specific AGM sera with similar
neutralizing activities reacted strongly with PVM G (Fig. 5B).
The PVM-neutralizing activity of human sera is not due to
PVM-specific IgG and IgM antibodies. Next, we evaluated the
specificity of the human test sera for PVM and RSV by a second
assay. Specifically, we evaluated reactivity against Vero cells that
had been infectedwith RSV or PVM, each of which expressedGFP
from an added gene. Reactivity was evaluated with intact, native
cells in suspension, thus maintaining antigen in native form. The
cells were then incubatedwith a secondary antibody conjugated to
Alexa 647. The cells were fixed and analyzed by flow cytometry to
compare the level of antibody reactivity with the level of viral
protein expression as indicated by GFP expression (Fig. 6).
First, we evaluated the reactivity of virus-specific control anti-
bodies (Fig. 6A). Three different RSV F MAbs (results are shown
in Fig. 6A for MAb 1129; results with the other two MAb were
similar and are not shown) each reacted strongly with RSV-GFP-
infected cells, and in each case the intensity of MAb binding cor-
related positively with the level of GFP expression. In contrast, the
RSV F MAbs did not react with rPVM-GFP infected cells regard-
less of the level of GFP expression (Fig. 6A). An isotype control
antibody yielded similar negative results (not shown). Rabbit an-
tiserum made against an MVA expressing the PVM G protein
(PVMG-specific PAb) reacted strongly with rPVM-GFP-infected
cells (Fig. 6A), and the level of antibody staining correlated posi-
tively with the level of GFP expression. The rabbit PVMG-specific
PAb did not react significantly with RSV-infected cells regardless
of the amount of GFP expression (Fig. 6A). Thus, RSV-specific
antibodies did not cross-react with PVM-infected cells, and vice
versa. This assay provided a sensitive means to detect virus-spe-
cific antibodies by correlating antibody binding with the level of
viral antigen expression as indicated by the GFP marker.
We then used this assay to evaluate RSV-positive and PVM-
positive AGM sera (serving as additional controls) and, more im-
portantly, a number of selected adult human test sera that were
RSV-seropositive and were either PVM seronegative or seroposi-
tive. First, binding was assessed with secondary antibodies specific
to IgG (Fig. 6B). A preimmune AGM control serum (Fig. 6B)
exhibited little or no IgG antibody binding to cells infected with
either virus compared to an antibody isotype control, indicating a
lack of virus-specific antibodies as expected (Fig. 6). In contrast,
when serum from an AGM that had been infected with RSV
(RSV	 PVM
; Fig. 6B) was evaluated with RSV-infected cells, it
exhibited strong IgG antibody binding, and the level of binding
increased concomitantly with increased GFP expression. In con-
trast, binding to PVM-infected cells (Fig. 6B) was only slightly
greater than that of preimmune serum or an isotype antibody
control (data not shown), and the level of binding did not increase
concomitantly with increased GFP expression. Conversely, serum
from an AGM that had been infected with PVM (RSV
 PVM	;
Fig. 6B) exhibited the opposite pattern: with PVM-infected cells,
IgG antibody binding was strong and increased concomitantly
with increased GFP expression, whereas binding to RSV-infected
cells was only slightly greater than that of preimmune serum or
isotype control antibody and did not increase concomitantly with
GFP expression. Thus, the postinfection RSV and PVMAGM sera
contained IgG antibodies specific to the respective virus, the level
of antibody binding increased concomitant with increased GFP
expression, and there was no significant cross-reactivity with the
heterologous virus.
Next, representative human sera were evaluated. Serum from
an infant that lacked RSV- or PVM-neutralizing activity (Fig. 6B)
exhibited a level of binding to either RSV-infected cells or PVM-
infected cells that was moderately higher than that of the isotype
antibody control (data not shown), but the level of binding did
not increase concomitantly with increased GFP expression. An
adult donor serum with a high RSV PRNT60 and low PVM
PRNT60 (RSV
	 PVMlo; Fig. 6B) exhibited strong binding against
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FIG 6 Evaluation of the binding activity of selected human sera to RSV- and PVM-infected cells by flow cytometry. Vero cells were infected at anMOI of 1 with
either RSV or PVM, each expressing GFP. Twenty-four hours postinfection, cells were detached with 1.0 mM EDTA. Infected cells were stained with selected
human test sera or control antibodies, followed by secondary antibodies conjugated to Alexa 647. The cells were then fixed and analyzed by flow cytometry to
compare the level of antibody binding (y axis) to GFP expression as a measure of viral gene expression (x axis). For each human or AGM serum, the reciprocal
log2 PRNT60 for RSV and PVM are noted. Results are representative of three independent experiments. Antibody isotype controls are not shown. (A) Antibody
controls. reactivity of RSV F-specific MAb 1169 (left) and PVM G-specific polyclonal antibody (right) with RSV-GFP- and PVM-GFP-infected cells (top and
bottom, respectively). (B and C) Analysis of AGM (left) and human (right) sera for IgG (B) or IgM (C) antibodies that react with RSV-GFP- and PVM-GFP-
infected cells. One example is shown for each of 6 categories of sera (columns from left to right): (i) preimmune AGM, (ii) RSV	 PVM
AGM, (iii) RSV
 PVM	
AGM, (iv) nonimmune human (from an infant), (v) RSV	PVMlo adult human, and (vi) RSV
PVM	 adult human. A total of 4 donors per categorywere tested,
with similar results; the data shown are for one representative individual.
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RSV-infected cells, and the level of staining increased concomi-
tantly with GFP expression. Against PVM-infected cells (Fig. 6B),
there was a moderate level of antibody staining, but the level of
staining did not increase with increased GFP expression. An adult
serum with a substantial RSV PRNT60 and one of the highest ob-
served PVM PRNT60 (RSV	 PVM
	; Fig. 6B) gave essentially the
same results: against RSV-infected cells, there was strong staining
that increased concomitantly with GFP expression, whereas
against PVM-infected cells, there was a moderate level of staining
that did not increase concomitantly with increased GFP expres-
sion. These results showed that, in this sensitive assay, the human
sera did not contain IgG antibodies that specifically reacted with
native PVM antigen, although there was a moderate level of IgG-
specific staining that was above that of naïve sera. The same ab-
sence of PVM-specific binding was observed with 3 additional
adult sera with PVM PRNT60 of 8.6, 7.7, and 7.9 log2 (data not
shown).
The same set of AGM and human sera were evaluated by this
assay using a secondary antibody specific to IgM (Fig. 6C). In this
case, a moderate level of background antibody binding was ob-
served for most of the sera against both RSV- and PVM-infected
cells. However, except in a single case, the level of antibody bind-
ing did not increase with increased GFP expression. The one ex-
ception was with AGM serum from an animal immunized with
PVM (RSV
 PVM	; Fig. 6C), for which antibody binding in-
creased, concomitant with increased GFP expression. This indi-
cated that, 28 days following primary infection with PVM, this
AGM contained PVM-specific serum IgM antibodies, which was
not completely unexpected. The lack of detectable virus-specific
serum IgM in other samples might be indicative of longer periods
of time since infection or exposure. In summary, the flow cyto-
metry results showed that the human sera did not contain IgG or
IgM antibodies that specifically reacted with PVM-infected cells
but that there was some weak IgG- and IgM-based reactivity that
could be consistent with the presence of low-affinity (possibly
natural) antibodies.
In the experiments described above, the AGM and human sera
were tested at a dilution of 1:100. We also evaluated these sera at
dilutions of 1:1,000 and 1:5,000 (data not shown). This showed
that themagnitude of the positive IgG and IgMfluorescent signals
decreasedwith increased dilution, demonstrating the specificity of
the results obtained.
PVM-neutralizing activity of human sera diminishes after
depletion of IgG. Finally, we investigated whether the observed
PVM-neutralizing activity was indeed associated with IgG anti-
bodies (Fig. 7A). IgG was removed using protein G Sepharose
columns, which binds to all four subclasses of IgG. To confirm
that IgG had indeed been depleted from the serum samples by
treatment with protein G, serum samples from before and after
treatment were electrophoresed on 4-to-12% SDS-PAGE gels un-
der nonreducing and nondenaturing conditions, the gels were
stainedwithCoomassie blue, and bandswere quantified (Fig. 7A).
IgG has a molecular mass range of 150 to 170 kDa; commercially
obtained purified human IgGwas used as amarker. The represen-
tative RSV-positive AGM serum (Fig. 7A, lanes 1) had a reduction
of 40%, and the representative PVM-positive AGMserum showed
a reduction in IgG band intensity of 66% (lanes 2). For the adult
human sera, the reduction in band intensity ranged from 41%
(lanes 5) to 79% (lanes 6).
Neutralization titers were compared in samples before and af-
ter being processed through the columns. First, we evaluated
AGM sera specific for RSV or PVM as monospecific positive con-
trols. This showed that the RSV-neutralizing activity of sera from
RSV-infected AGM decreased below background levels following
depletion of IgG. The PVM-neutralizing activity of sera from
PVM-infected AGM also was reduced by treatment with protein
G. The posttreatment titers of PVM-neutralizing antibodies did
not fall below background, but this was likely due to the presence
of IgM antibodies, as shown in Fig. 6C. Next, the 12 adult serum
samples with PVM-neutralizing activity were investigated for
RSV- and PVM-neutralizing activity after depletion of IgG. Mean
PRNT60 of RSV-neutralizing antibodies were reduced from 9.2
log2 to 7.5 log2, and mean PRNT60 of PVM-neutralizing antibod-
ies were reduced from 6.7 log2 to 3.9 log2. RSV and PVM neutral-
ization titers of human sera before and after IgG depletion were
compared using a paired t test. The reduction in neutralizing ac-
tivity was significant in both instances (P 0.0001). In summary,
removal of IgG from adult sera resulted in a concomitant reduc-
tion in PVM- and RSV-neutralizing activity.
DISCUSSION
Newhuman respiratory pathogens, such as humanmetapneumo-
virus (65), human bocavirus (1), and additional human corona-
virus species (21, 43, 66, 68), continue to be identified.However, it
is estimated that 14 to 23% of viral infections of the lower respi-
ratory tract lack an identified etiologic agent (54). Previous studies
indicated that a substantial proportion of human serum samples
had PVM-neutralizing activity. This suggested that humans are
commonly infected with PVM, or with a virus related to PVM.
However, there has never been a report of the isolation or direct
detection of PVM in humans. Also, as noted in the introduction,
the previous serological surveys had limitations. Therefore, we
revisited the question of whether PVMmight be a common agent
of infection in humans.
Two species of nonhuman primates, namely, AGM and RM,
were inoculated via the respiratory tract with a high dose of PVM.
Virus was shed sporadically and at very low titers, and some ani-
mals failed to shed any detectable virus. This suggested that virus
replication was highly restricted, although this is offered with the
caveat that we did not sacrifice the animals and measure virus
titers directly in lung tissue. Infection of humans by human respi-
ratory viruses, such as RSV, parainfluenza viruses, and influenza
virus, results in the shedding of substantial titers of virus in respi-
ratory secretions, and this is a commonly used measure of repli-
cation. Infection of nonhuman primates with human respiratory
viruses also results in titers of shed virus that are substantial, al-
though lower than those observed with humans. In the case of the
severe acute respiratory syndrome (SARS) coronavirus, which in-
fects humans and causes serious disease but is not a natural human
pathogen, we and others observed consistent shedding, although
at levels that are lower than those observed with human viruses
(11, 47). In contrast, the very low and sporadic shedding that we
observed in the present study is similar to what we previously
observed in AGM and RM with Newcastle disease virus, which is
an avian virus (10), or in chimpanzees with bovine RSV (8). In the
case of SARS coronavirus and NDV, somewhat higher viral titers
were detected when animals were sacrificed and respiratory tract
tissue was assayed directly, but the levels of shed virus were pre-
dictive. Therefore, the present data suggest that the permissiveness
of primates for PVM is similar to that for the avian Newcastle
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disease virus and bovine RSV. Thus, PVMappears to have a strong
host range restriction in primates. Interestingly, infection of the
AGM and RM with PVM in the present study resulted in ex-
tremely high titers of PVM-neutralizing serum antibodies. The
basis for this is not known. One possibility is that viruses may
mutate to lose highly immunogenic B- and T-cell epitopes in re-
sponse to selective immune pressure during evolution in a natural
host butmay bemore immunogenic in nonnatural hosts in which
this selection has not occurred.However, this remains speculative.
The block to PVM infection in nonhuman primates did not
appear to be due to an inability to infect and replicate in primate
cells. As noted, a number of previous studies employed a variant of
PVM that had been adapted to replicate on AGM BSC-1 cells (14,
15, 64); however, this adapted virus had sustained extensive mu-
tations (64) and thusmay have an altered host range. For example,
a single amino acid change in lymphocytic choriomeningitis virus
was sufficient to alter tropism (63). PVM that had been propa-
gated on hamster BHK cells was previously shown to replicate
efficiently in AGM Vero cells (6), although these cells lack the
ability to produce type 1 IFN and thus do not provide a strict test.
In the present study, we found that preparations of PVM that had
been grown on BHK cells and confirmed to be virulent in mice
FIG 7 Evaluation of RSV- and PVM-neutralizing activity in human serum samples after partial depletion of IgG antibodies. Human sera previously identified
as having PVM-neutralizing activity were passed through protein G Sepharose columns to partially remove IgG antibodies. Sera from RSV- and PVM-infected
AGM served asmonospecific controls. Some donors are identified by numbers, located below the lanes (A) and above the dots (B), to allow comparison between
titers of neutralizing antibodies and level of IgG depletion. (B) PRNT60 for PVM and RSV were measured before and after IgG depletion. Sera with a PRNT60 of
5.3 log2 (1:40) were considered seropositive (dashed line). Data are from a single titration experiment; a second experiment provided similar results. (A)
Analysis of IgG content by 4-to-12% SDS-PAGE gel electrophoresis under nonreducing and nondenaturing conditions, with commercially obtained purified
human IgG as amarker. Gels were stained with Coomassie blue. The reductions in IgG band intensity for the numbered samples were as follows: 1, 80%; 2, 88%;
3, 76%; 4, 45%; 5, 41%; and 6, 79%. ****, P 0.0001.
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replicated in human airway epithelial A549 cells with an efficiency
equivalent to what we typically observe with RSV. While these
observations suggest that there is no major block to PVM infec-
tion and replication in primate cells, there is the caveat that infec-
tion of cell lines can be an unreliable predictor of host range and
that for cell lines can be more permissive than the intact host. In
some instances, for example, virus entry in cultured cell lines can
be mediated by alternative cellular receptors that are irrelevant in
vivo (53, 58). In human airway epithelial primary cell cultures,
PVM was marginally infectious (Raymond Pickles [University of
North Carolina, Chapel Hill, NC], personal communication).
However, these primary human airway cultures represent the dif-
ferentiated cartilaginous respiratory epithelium (71). It will be of
interest to further evaluate the permissiveness for PVM infection
in primary models of the human distal respiratory tract.
The ability of PVM to infect A549 cells provided the opportu-
nity to investigate its ability to block the human IFN response.
This was of interest because, for viruses in general, the ability to
block the host IFN response is usually important for efficient rep-
lication. Surprisingly, PVM was highly effective in inhibiting IFN
production in A549 cells, which is a common model for studying
IFN responses. The use of NS deletion PVMmutants showed that
the NS2 protein played the major role in inhibiting the human
IFN response, as was also the case in murine cells. Thus, the re-
striction of PVM in nonhuman primates does not appear to be
due an inability of the virus to inhibit the IFN response in these
nonrodent hosts. The basis for the host range restriction of a
paramyxovirus was previously studied in detail for bovine parain-
fluenza virus (BPIV3), which is restricted for replication in hu-
mans and nonhuman primates such as RM (67). This was ana-
lyzed by systematically replacing each gene of HPIV3 with that of
BPIV3, followed by evaluation of the chimeras in RM. The results
showed that each of the genes made a contribution to the host
range restriction (60). This suggested that the restriction does not
involve a single major block at any specific step in infection and
replication but rather is the aggregate effect of suboptimal func-
tioning of multiple viral components in the nonnative host. The
same might be true for PVM.
We evaluated a panel of adult human sera for RSV and PVM
neutralization activity. As expected, all of the samples had high
RSV-neutralizing activity, indicative of prior exposure to this
ubiquitous human pathogen. In addition, approximately 40%
had moderate PVM-neutralizing activity, and the rest lacked sig-
nificant PVM-neutralizing activity. We also analyzed sera from
infants and young children and found that 41% were seropositive
for RSV, while only one individual was seropositive for PVM. The
increased incidence of seropositivity with increased age raised the
possibility that exposure to PVMor a PVM-like virusmight occur
between early childhood and adulthood. However, as noted, the
PVM-neutralizing activity was low.
We evaluated the possibility that the observed PVM-neutraliz-
ing activity was due to cross-neutralization by RSV-specific anti-
bodies. Three lines of evidence suggested that this was not the case.
First, there was no correlation between high titers of RSV-neutral-
izing antibodies and PVM-neutralizing activity in the human se-
rum samples. Second, no cross-neutralizing activity was observed
between monospecific antisera from AGM or RM that had been
infected with RSV or PVM. Third, no cross-protection was ob-
served inmice that had a primary infection with RSV or PVM and
were cross-challenged with the heterologous virus. Thus, while a
low level of cross-reactivity was observed with the N proteins of
the two viruses, there was no evidence of cross-neutralization or
cross-protection in vitro or in vivo.
We investigated the specificity of the PVM-neutralizing activ-
ity by evaluating reactivity with Western blots of PVM and RSV
proteins that had been prepared from purified virions under
nonreducing and nonneutralizing conditions. The Western blot
analysis did not provide evidence of PVM-specific antibodies in
human sera. None of the AGMor human sera exhibited any cross-
reactivity between RSV and PVM in this Western blot analysis,
although, as noted, a low level of cross-reactivity for the N protein
was observed with rabbit antisera prepared by repeated immuni-
zation with purified virions of either virus. We also investigated
the specificity of the PVM-neutralizing sera by reactivity with
Vero cells that had been infected with PVMor RSV that expressed
GFP. Using the monospecific sera from RSV- and PVM-infected
AGMas controls, we showed that themagnitude of binding of IgG
correlated with the intensity of GFP expression in cells infected
with the homologous GFP-expressing virus, consistent with the
expectation that the binding of virus-specific IgG would increase
with increased expression of viral antigens.With the adult human
sera, all of the samples tested contained IgG antibodies that bound
to RSV-GFP-infected cells, and we similarly observed a linear cor-
relation between IgG binding and the level of GFP expression.
With PVM-GFP-infected cells, both the PVM-neutralizing and
nonneutralizing adult human sera exhibited a low, background
level of binding of serum IgG antibodies, and the level of binding
did not increase with increasing GFP expression. This was sugges-
tive of low-affinity, non-PVM-specific binding activity. In addi-
tion, we detected only a low level of binding of IgM serum anti-
bodies with all of the sera, with the single exception that day 28
sera fromPVM-infectedAGMexhibited substantial PVM-specific
IgM binding. Apart from that single exception, binding did not
correlate with GFP expression, indicating an absence of RSV- or
PVM-specific IgM.
When we began these studies, we anticipated several possible
outcomes: (i) that cells of nonhuman primates would be permis-
sive for PVM and that PVMmight be a true human pathogen; (ii)
that humansmight not be fully permissive for PVMbut that PVM
might cause incidental infection, similar to the situation with
NDV, which can infect and cause generally mild disease in hu-
mans with substantial exposure to the virus but which is not a
natural human virus; (iii) that a relative of PVM might infect
humans; or (iv) that the reported seropositivitymight not be PVM
specific. The results of the present study support the last conclu-
sion. The idea that PVM might be an authentic human pathogen
seems inconsistentwith the lack of permissive infection inRMand
AGM. The idea that PVMmight be a cause of incidental infection
in humans is inconsistent with the lack of reactivity with PVM
proteins in Western blot or with PVM-infected cells. These same
data also speak against the idea that the putative seropositivity
might reflect cross-reactivity with a relative of PVM, since that
cross-reactivity should have been evident in Western blots.
It is possible that the PVM-neutralizing activity detected in
human sera might reflect natural antibodies (46, 51). Natural an-
tibodies are polyreactive, with specificity for multiple different
antigens (25, 51). They are produced by B1 cells independent of
exogenous antigens, have not undergone affinity maturation, and
usually have low affinity for antigen (72).Natural antibodies are of
broad specificity. They frequently react with carbohydrate anti-
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gens and provide a first line of defense against infections by acti-
vating the complement pathway (24). It is true that natural anti-
bodies are often of the IgM subclass, but they can also be of the IgG
subclass. Natural polyreactive and autoreactive antibodies are
present at birth, representing a contribution of IgG natural anti-
bodies that are of maternal origin as well as a universal congenital
IgM profile. Endogenous IgG develops with age, and both the IgG
and IgM natural antibody repertoires become more diverse dur-
ing life (45). This could explain why the low PVM-neutralizing
activity of human sera seemed to develop with age.
In summary, we report that the basis of the PVM-neutralizing
activity of human sera is not due to high-affinity PVM-specific
antibodies or to RSV-specific antibodies cross-reacting with
PVM. The PVM-neutralizing activity may be due to low-affinity,
polyreactive natural antibodies. It seems very unlikely that PVM is
a human pathogen, given its poor replication in nonhuman pri-
mates and the lack of any report of isolation or direct detection in
humans. This high level of restriction did not appear to be due to
a strong block at the level of infection or IFN antagonism. It also
seems unlikely that PVM, or a PVM relative, may incidentally
infect humans, given the lack of confirmed PVM-specific serum
antibodies. Interestingly, PVMmight be useful as a vaccine vector
for human immunization via the respiratory tract, since it repli-
cates at low levels and is highly immunogenic. The presence of low
levels of PVM-neutralizing serum natural antibodies likely would
not be an obstacle to this, since serumantibodies are not efficiently
transported to the respiratory lumen and have reduced efficiency
in restricting respiratory virus replication.
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